Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and

 Upcoming Conferences, Share Price Updates, and Leadership Changes - Research
   Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 8, 2014

NEW YORK, January 8, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Eli Lilly
& Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Waters Corp. (NYSE: WAT),
Novavax, Inc. (NASDAQ: NVAX), and Supernus Pharmaceuticals, Inc. (NASDAQ:
SUPN). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Eli Lilly & Co. Research Report

On January 2, 2014, Eli Lilly & Co. (Lilly) reported that it will announce its
2014 financial guidance and financial results for Q4 2013 and full year of
2013, on January 7, 2014 and January 30, 2014, respectively. The Company
stated that it will also hold conference calls with the investment community
and media to further discuss its 2014 financial guidance and its 2013
financial performance, respectively, on both days at 9:00 a.m. EST. Lilly
added that live webcasts of the calls can be accessed via the Company website.
The Full Research Report on Eli Lilly & Co. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

--

Allergan Inc. Research Report

On January 3, 2014, Allergan Inc.'s (Allergan) stock climbed 1.61%, ending the
day at $112.06. Over the previous three trading sessions, shares of Allergan
rose 1.18%, compared to the Dow Jones industrial average, which declined 0.21%
during the same period. The Full Research Report on Allergan Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/182a_AGN

--

Waters Corp. Research Report

On January 3, 2014, Waters Corp.'s (Waters) stock declined 1.19%, ending the
day at $98.04. Over the previous three trading sessions, shares of Waters fell
2.25%, compared to the Dow Jones industrial average which declined 0.21%
during the same period. The Full Research Report on Waters Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/2fff_WAT

--

Novavax, Inc. Research Report

On January 3, 2014, Novavax, Inc.'s (Novavax) stock rose 1.92%, ending the day
at $5.31. Over the previous three trading sessions, shares of Novavax climbed
2.91%, compared to the Nasdaq Composite which declined 0.54% during the same
period. The Full Research Report on Novavax, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/bc35_NVAX

--

Supernus Pharmaceuticals, Inc. Research Report

On December 24, 2013, Supernus Pharmaceuticals, Inc. (Supernus) announced the
resignation of Michael Bigham, a General Partner at Abingworth, from the
Company's Board of Directors, effective December 23, 2013. Michael Bigham
stated, "Abingworth remains a significant shareholder in Supernus but as a
matter of general practice we limit the time we spend on the boards of our
portfolio companies once they have become public companies." CEO, President
and Director of Supernus, Jack Khattar, commented, "Since joining the Supernus
Board of Directors in 2006, Michael Bigham has been a great contributor
providing the Board with great insight and judgment based on his vast
experience in the healthcare industry. We will miss him, and are grateful for
his service." The Full Research Report on Supernus Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ccb_SUPN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)